Form 4: ProMIS Neurosciences Insider Michael Gordon Acquires Shares and Warrants in Private Placement

Michael S. Gordon, a director of ProMIS Neurosciences, acquired common shares and warrants through a private placement and conversion of preferred shares on July 31, 2024.

Summary

• On July 31, 2024, Michael S. Gordon, a director of ProMIS Neurosciences, acquired 465,116 units in a private placement.
• Each unit consisted of one common share, one Tranche A warrant, one Tranche B warrant, and one Tranche C warrant.
• The purchase price for each unit was $2.15.
• Gordon also acquired 500,000 common shares through the conversion of Series 2 Preferred Shares, which converted at a 1:1 ratio due to a qualified equity financing exceeding $14 million.
• Following these transactions, Gordon indirectly owns 2,075,629 common shares through Title 19 Promis and 48,333 common shares through Title 19 Acies, both Delaware LLCs where he is the sole manager.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document primarily reports on insider transactions related to a previously announced financing. The insider participation is a positive signal, but the potential dilution from warrant exercises is a concern.

Positives

• Insider participation in the private placement may signal confidence in the company's prospects.
• The conversion of preferred shares into common shares simplifies the capital structure.
• The company has secured over $14 million in qualified equity financing.

Risks

• The Tranche A and B warrants are contingent on shareholder approval and data from PMN310 trials, creating uncertainty regarding their exercisability.
• The warrants could lead to dilution of existing shareholders if exercised.

Future Outlook

The exercisability of Tranche A and B warrants depends on future shareholder approval and clinical trial data from PMN310.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's view of the company's prospects. Private placements are a common way for biotech companies to raise capital.

Comparison to Industry Standards

• Comparing the terms of the warrants (exercise price, expiration date) to similar biotech companies' financing deals would provide a benchmark for assessing the attractiveness of this offering.
• For example, warrant coverage and exercise prices can be compared to recent private placements by companies like Cassava Sciences or Anavex Life Sciences, which are also focused on neurodegenerative diseases.
• The $14 million equity financing can be compared to the average size of Series A or B rounds for biotech companies in the neurosciences space.

Stakeholder Impact

• Existing shareholders may experience dilution if the warrants are exercised.
• The company's financial position is strengthened by the equity financing.

Next Steps

• Shareholder approval may be required for the issuance of shares upon exercise of Tranche A and B warrants.
• Monitoring of clinical trial data from PMN310 to determine the exercisability of Tranche A and B warrants.

Key Dates